GlassScriptPhysician profile
James Donald Mcleod
NPI 1639183700
$6,420.69
in general payments reported to CMS, 2019-2025
47 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $1,569 · 2021: $1,477 · 2022: $878 · 2023: $216 · 2024: $374 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,116.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $571.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $421.16 | 2019-2022 | |
| Organogenesis INC. | $315.01 | 2024-2025 | Apligraf, Puraply Wound Matrix, Puraply Franchise |
| Abbvie INC. | $306.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $283.10 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.57 | 2019-2022 | |
| Viiv Healthcare Company | $194.38 | 2019-2021 | |
| Allergan, INC. | $190.95 | 2019-2020 | |
| Amarin Pharma, INC. | $188.13 | 2019-2021 | |
| Smith+Nephew, INC. | $183.08 | 2019-2025 | Grafix Pl, Grafix, Stravix Pl |
| Pfizer INC. | $166.02 | 2019-2022 | |
| Astellas Pharma US INC | $164.86 | 2019-2021 | |
| Lilly USA, LLC | $164.57 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $160.06 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.